Silent Liver Threat: Millions Unaware of MASLD

Metabolic-associated steatotic liver disease (MASLD), previously known as NAFLD, is emerging as the most prevalent chronic liver condition globally. Affecting an estimated 30% to 40% of adults worldwide, this disease develops when excess fat accumulates in the liver, particularly in individuals with underlying metabolic issues like obesity and type 2 diabetes. It is distinct from alcohol-related liver disease.

The ramifications of MASLD extend beyond the liver, significantly increasing the risk of heart disease, stroke, and certain cancers. While early symptoms are often vague, such as fatigue, significant liver damage can progress to cirrhosis, liver failure, or liver cancer over time. Routine blood tests and ultrasounds can initially flag concerns, prompting further metabolic assessments.

Encouragingly, MASLD can often be managed and improved with early intervention. Weight loss is considered the primary treatment, alongside regular physical activity. Lifestyle modifications, including a healthy diet and managing existing conditions like diabetes and high blood pressure, are vital. Two medications have recently gained approval for more advanced stages, but foundational lifestyle changes remain essential for recovery.